Carbon-ion radiation therapy for prostate cancer

Hitoshi Ishikawa, Hiroshi Tsuji, Tadashi Kamada, Koichiro Akakura, Hiroyoshi Suzuki, Jun Shimazaki, Hirohiko Tsujii, Jun Shimazaki, Koichiro Akakura, Tetsuo Akimoto, Tomohiko Ichikawa, Tatsuo Igarashi, Koji Kawamura, Takeshi Ueda, Mototsugu Oya, Hideyuki Sakurai, Mizuki Onozawa, Chihiro Kanehira, Koichi Kamura, Hiroyoshi SuzukiKazumasa Nakamura, Masaoki Harada, Makoto Fujime, Ken Marumo, Hirohiko Tsujii, Tadashi Kamada, Hiroshi Tsuji

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

In 1994, carbon-ion radiotherapy was started at the National Institute of Radiological Sciences using the Heavy-Ion Medical Accelerator in Chiba. Between June 1995 and March 2000, two phaseI/II dose escalation studies (protocols 9402 and 9703) of hypofractionated carbon-ion radiotherapy for both early- and advance-stage prostate cancer patients had been carried out to establish radiotherapy technique and to determine the optimal radiation dose. To validate the feasibility and efficacy of hypofractionated carbon-ion radiotherapy, a phaseII study (9904) was initiated in April 2000 using the shrinking field technique and the recommended dose fractionation (66 gray equivalents in 20 fractions over 5weeks) obtained from the phaseI/II studies, and was successfully completed in October 2003. The data from 175 patients in the phaseII study showed the importance of an appropriate use of androgen deprivation therapy according to tumor risk group. Since November 2003, carbon-ion radiotherapy for prostate cancer was approved as "Highly Advanced Medical Technology" from the Ministry of Health, Labor, and Welfare, and since then approximately 1100 patients have received carbon-ion radiotherapy as of July 2011. In this review, we introduce our steps thorough three clinical trials carried out at National Institute of Radiological Sciences, and show the updated data of carbon-ion radiotherapy obtained from approximately 1000 prostate cancer patients. In addition, our recent challenge and future direction will be also described.

Original languageEnglish
Pages (from-to)296-305
Number of pages10
JournalInternational Journal of Urology
Volume19
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Fingerprint

Heavy Ion Radiotherapy
Prostatic Neoplasms
Dose Fractionation
Heavy Ions
Biomedical Technology
Androgens
Radiotherapy
Clinical Trials
Radiation

Keywords

  • Androgen deprivation therapy
  • Carbon-ion radiation therapy
  • Hypofractionation
  • Prostate cancer
  • Survival

ASJC Scopus subject areas

  • Urology

Cite this

Ishikawa, H., Tsuji, H., Kamada, T., Akakura, K., Suzuki, H., Shimazaki, J., ... Tsuji, H. (2012). Carbon-ion radiation therapy for prostate cancer. International Journal of Urology, 19(4), 296-305. https://doi.org/10.1111/j.1442-2042.2012.02961.x

Carbon-ion radiation therapy for prostate cancer. / Ishikawa, Hitoshi; Tsuji, Hiroshi; Kamada, Tadashi; Akakura, Koichiro; Suzuki, Hiroyoshi; Shimazaki, Jun; Tsujii, Hirohiko; Shimazaki, Jun; Akakura, Koichiro; Akimoto, Tetsuo; Ichikawa, Tomohiko; Igarashi, Tatsuo; Kawamura, Koji; Ueda, Takeshi; Oya, Mototsugu; Sakurai, Hideyuki; Onozawa, Mizuki; Kanehira, Chihiro; Kamura, Koichi; Suzuki, Hiroyoshi; Nakamura, Kazumasa; Harada, Masaoki; Fujime, Makoto; Marumo, Ken; Tsujii, Hirohiko; Kamada, Tadashi; Tsuji, Hiroshi.

In: International Journal of Urology, Vol. 19, No. 4, 04.2012, p. 296-305.

Research output: Contribution to journalArticle

Ishikawa, H, Tsuji, H, Kamada, T, Akakura, K, Suzuki, H, Shimazaki, J, Tsujii, H, Shimazaki, J, Akakura, K, Akimoto, T, Ichikawa, T, Igarashi, T, Kawamura, K, Ueda, T, Oya, M, Sakurai, H, Onozawa, M, Kanehira, C, Kamura, K, Suzuki, H, Nakamura, K, Harada, M, Fujime, M, Marumo, K, Tsujii, H, Kamada, T & Tsuji, H 2012, 'Carbon-ion radiation therapy for prostate cancer', International Journal of Urology, vol. 19, no. 4, pp. 296-305. https://doi.org/10.1111/j.1442-2042.2012.02961.x
Ishikawa H, Tsuji H, Kamada T, Akakura K, Suzuki H, Shimazaki J et al. Carbon-ion radiation therapy for prostate cancer. International Journal of Urology. 2012 Apr;19(4):296-305. https://doi.org/10.1111/j.1442-2042.2012.02961.x
Ishikawa, Hitoshi ; Tsuji, Hiroshi ; Kamada, Tadashi ; Akakura, Koichiro ; Suzuki, Hiroyoshi ; Shimazaki, Jun ; Tsujii, Hirohiko ; Shimazaki, Jun ; Akakura, Koichiro ; Akimoto, Tetsuo ; Ichikawa, Tomohiko ; Igarashi, Tatsuo ; Kawamura, Koji ; Ueda, Takeshi ; Oya, Mototsugu ; Sakurai, Hideyuki ; Onozawa, Mizuki ; Kanehira, Chihiro ; Kamura, Koichi ; Suzuki, Hiroyoshi ; Nakamura, Kazumasa ; Harada, Masaoki ; Fujime, Makoto ; Marumo, Ken ; Tsujii, Hirohiko ; Kamada, Tadashi ; Tsuji, Hiroshi. / Carbon-ion radiation therapy for prostate cancer. In: International Journal of Urology. 2012 ; Vol. 19, No. 4. pp. 296-305.
@article{518253ede4854e0aa5be275fb6b0a951,
title = "Carbon-ion radiation therapy for prostate cancer",
abstract = "In 1994, carbon-ion radiotherapy was started at the National Institute of Radiological Sciences using the Heavy-Ion Medical Accelerator in Chiba. Between June 1995 and March 2000, two phaseI/II dose escalation studies (protocols 9402 and 9703) of hypofractionated carbon-ion radiotherapy for both early- and advance-stage prostate cancer patients had been carried out to establish radiotherapy technique and to determine the optimal radiation dose. To validate the feasibility and efficacy of hypofractionated carbon-ion radiotherapy, a phaseII study (9904) was initiated in April 2000 using the shrinking field technique and the recommended dose fractionation (66 gray equivalents in 20 fractions over 5weeks) obtained from the phaseI/II studies, and was successfully completed in October 2003. The data from 175 patients in the phaseII study showed the importance of an appropriate use of androgen deprivation therapy according to tumor risk group. Since November 2003, carbon-ion radiotherapy for prostate cancer was approved as {"}Highly Advanced Medical Technology{"} from the Ministry of Health, Labor, and Welfare, and since then approximately 1100 patients have received carbon-ion radiotherapy as of July 2011. In this review, we introduce our steps thorough three clinical trials carried out at National Institute of Radiological Sciences, and show the updated data of carbon-ion radiotherapy obtained from approximately 1000 prostate cancer patients. In addition, our recent challenge and future direction will be also described.",
keywords = "Androgen deprivation therapy, Carbon-ion radiation therapy, Hypofractionation, Prostate cancer, Survival",
author = "Hitoshi Ishikawa and Hiroshi Tsuji and Tadashi Kamada and Koichiro Akakura and Hiroyoshi Suzuki and Jun Shimazaki and Hirohiko Tsujii and Jun Shimazaki and Koichiro Akakura and Tetsuo Akimoto and Tomohiko Ichikawa and Tatsuo Igarashi and Koji Kawamura and Takeshi Ueda and Mototsugu Oya and Hideyuki Sakurai and Mizuki Onozawa and Chihiro Kanehira and Koichi Kamura and Hiroyoshi Suzuki and Kazumasa Nakamura and Masaoki Harada and Makoto Fujime and Ken Marumo and Hirohiko Tsujii and Tadashi Kamada and Hiroshi Tsuji",
year = "2012",
month = "4",
doi = "10.1111/j.1442-2042.2012.02961.x",
language = "English",
volume = "19",
pages = "296--305",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Carbon-ion radiation therapy for prostate cancer

AU - Ishikawa, Hitoshi

AU - Tsuji, Hiroshi

AU - Kamada, Tadashi

AU - Akakura, Koichiro

AU - Suzuki, Hiroyoshi

AU - Shimazaki, Jun

AU - Tsujii, Hirohiko

AU - Shimazaki, Jun

AU - Akakura, Koichiro

AU - Akimoto, Tetsuo

AU - Ichikawa, Tomohiko

AU - Igarashi, Tatsuo

AU - Kawamura, Koji

AU - Ueda, Takeshi

AU - Oya, Mototsugu

AU - Sakurai, Hideyuki

AU - Onozawa, Mizuki

AU - Kanehira, Chihiro

AU - Kamura, Koichi

AU - Suzuki, Hiroyoshi

AU - Nakamura, Kazumasa

AU - Harada, Masaoki

AU - Fujime, Makoto

AU - Marumo, Ken

AU - Tsujii, Hirohiko

AU - Kamada, Tadashi

AU - Tsuji, Hiroshi

PY - 2012/4

Y1 - 2012/4

N2 - In 1994, carbon-ion radiotherapy was started at the National Institute of Radiological Sciences using the Heavy-Ion Medical Accelerator in Chiba. Between June 1995 and March 2000, two phaseI/II dose escalation studies (protocols 9402 and 9703) of hypofractionated carbon-ion radiotherapy for both early- and advance-stage prostate cancer patients had been carried out to establish radiotherapy technique and to determine the optimal radiation dose. To validate the feasibility and efficacy of hypofractionated carbon-ion radiotherapy, a phaseII study (9904) was initiated in April 2000 using the shrinking field technique and the recommended dose fractionation (66 gray equivalents in 20 fractions over 5weeks) obtained from the phaseI/II studies, and was successfully completed in October 2003. The data from 175 patients in the phaseII study showed the importance of an appropriate use of androgen deprivation therapy according to tumor risk group. Since November 2003, carbon-ion radiotherapy for prostate cancer was approved as "Highly Advanced Medical Technology" from the Ministry of Health, Labor, and Welfare, and since then approximately 1100 patients have received carbon-ion radiotherapy as of July 2011. In this review, we introduce our steps thorough three clinical trials carried out at National Institute of Radiological Sciences, and show the updated data of carbon-ion radiotherapy obtained from approximately 1000 prostate cancer patients. In addition, our recent challenge and future direction will be also described.

AB - In 1994, carbon-ion radiotherapy was started at the National Institute of Radiological Sciences using the Heavy-Ion Medical Accelerator in Chiba. Between June 1995 and March 2000, two phaseI/II dose escalation studies (protocols 9402 and 9703) of hypofractionated carbon-ion radiotherapy for both early- and advance-stage prostate cancer patients had been carried out to establish radiotherapy technique and to determine the optimal radiation dose. To validate the feasibility and efficacy of hypofractionated carbon-ion radiotherapy, a phaseII study (9904) was initiated in April 2000 using the shrinking field technique and the recommended dose fractionation (66 gray equivalents in 20 fractions over 5weeks) obtained from the phaseI/II studies, and was successfully completed in October 2003. The data from 175 patients in the phaseII study showed the importance of an appropriate use of androgen deprivation therapy according to tumor risk group. Since November 2003, carbon-ion radiotherapy for prostate cancer was approved as "Highly Advanced Medical Technology" from the Ministry of Health, Labor, and Welfare, and since then approximately 1100 patients have received carbon-ion radiotherapy as of July 2011. In this review, we introduce our steps thorough three clinical trials carried out at National Institute of Radiological Sciences, and show the updated data of carbon-ion radiotherapy obtained from approximately 1000 prostate cancer patients. In addition, our recent challenge and future direction will be also described.

KW - Androgen deprivation therapy

KW - Carbon-ion radiation therapy

KW - Hypofractionation

KW - Prostate cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84863407158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863407158&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2012.02961.x

DO - 10.1111/j.1442-2042.2012.02961.x

M3 - Article

C2 - 22320843

AN - SCOPUS:84863407158

VL - 19

SP - 296

EP - 305

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 4

ER -